160 related articles for article (PubMed ID: 33727843)
1. GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice.
Nakamura T; Tanimoto H; Okamoto M; Takeuchi M; Tsubamoto Y; Noda H
Diabetes Metab Syndr Obes; 2021; 14():1095-1105. PubMed ID: 33727843
[TBL] [Abstract][Full Text] [Related]
2. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo.
Nakamura T; Tanimoto H; Mizuno Y; Tsubamoto Y; Noda H
Diabetes Obes Metab; 2012 Jun; 14(6):511-7. PubMed ID: 22192426
[TBL] [Abstract][Full Text] [Related]
3. Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice.
Nakamura T; Tanimoto H; Mizuno Y; Okamoto M; Takeuchi M; Tsubamoto Y; Noda H
Obes Sci Pract; 2018 Apr; 4(2):194-203. PubMed ID: 29670757
[TBL] [Abstract][Full Text] [Related]
4. Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight.
Szalowska E; Meijer K; Kloosterhuis N; Razaee F; Priebe M; Vonk RJ
Peptides; 2011 May; 32(5):938-45. PubMed ID: 21334410
[TBL] [Abstract][Full Text] [Related]
5. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.
Gault VA; McClean PL; Cassidy RS; Irwin N; Flatt PR
Diabetologia; 2007 Aug; 50(8):1752-62. PubMed ID: 17558485
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent insulinotropic polypeptide is required for moderate high-fat diet- but not high-carbohydrate diet-induced weight gain.
Maekawa R; Ogata H; Murase M; Harada N; Suzuki K; Joo E; Sankoda A; Iida A; Izumoto T; Tsunekawa S; Hamada Y; Oiso Y; Inagaki N; Arima H; Hayashi Y; Seino Y
Am J Physiol Endocrinol Metab; 2018 Jun; 314(6):E572-E583. PubMed ID: 29406782
[TBL] [Abstract][Full Text] [Related]
7. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
McClean PL; Irwin N; Cassidy RS; Holst JJ; Gault VA; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1746-55. PubMed ID: 17848629
[TBL] [Abstract][Full Text] [Related]
8. Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in
Shimazu-Kuwahara S; Harada N; Yamane S; Joo E; Sankoda A; Kieffer TJ; Inagaki N
Mol Metab; 2017 Mar; 6(3):288-294. PubMed ID: 28271035
[TBL] [Abstract][Full Text] [Related]
9. GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism.
Boer GA; Keenan SN; Miotto PM; Holst JJ; Watt MJ
Am J Physiol Endocrinol Metab; 2021 Apr; 320(4):E835-E845. PubMed ID: 33645252
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed mice.
Boer GA; Hunt JE; Gabe MBN; Windeløv JA; Sparre-Ulrich AH; Hartmann B; Holst JJ; Rosenkilde MM
Br J Pharmacol; 2022 Sep; 179(18):4486-4499. PubMed ID: 35710141
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein lipase in rats fed fish oil: apparent relationship to plasma insulin levels.
Baltzell JK; Wooten JT; Otto DA
Lipids; 1991 Apr; 26(4):289-94. PubMed ID: 1865765
[TBL] [Abstract][Full Text] [Related]
12. Prevention of diet-induced obesity by dietary isomerized hop extract containing isohumulones, in rodents.
Yajima H; Noguchi T; Ikeshima E; Shiraki M; Kanaya T; Tsuboyama-Kasaoka N; Ezaki O; Oikawa S; Kondo K
Int J Obes (Lond); 2005 Aug; 29(8):991-7. PubMed ID: 15852044
[TBL] [Abstract][Full Text] [Related]
13. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
[TBL] [Abstract][Full Text] [Related]
14. Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.
Matikainen N; Söderlund S; Björnson E; Bogl LH; Pietiläinen KH; Hakkarainen A; Lundbom N; Eliasson B; Räsänen SM; Rivellese A; Patti L; Prinster A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
Nutr Metab Cardiovasc Dis; 2017 Jun; 27(6):534-542. PubMed ID: 28428027
[TBL] [Abstract][Full Text] [Related]
15. Increasing adipocyte lipoprotein lipase improves glucose metabolism in high fat diet-induced obesity.
Walton RG; Zhu B; Unal R; Spencer M; Sunkara M; Morris AJ; Charnigo R; Katz WS; Daugherty A; Howatt DA; Kern PA; Finlin BS
J Biol Chem; 2015 May; 290(18):11547-56. PubMed ID: 25784555
[TBL] [Abstract][Full Text] [Related]
16. Purified chickpea or lentil proteins impair VLDL metabolism and lipoprotein lipase activity in epididymal fat, but not in muscle, compared to casein, in growing rats.
Boualga A; Prost J; Taleb-Senouci D; Krouf D; Kharoubi O; Lamri-Senhadji M; Belleville J; Bouchenak M
Eur J Nutr; 2009 Apr; 48(3):162-9. PubMed ID: 19165521
[TBL] [Abstract][Full Text] [Related]
17. Effects of calcium salts of palm oil inclusion and ad libitum feeding regimen on growth performance, carcass characteristics, and plasma glucose-dependent insulinotropic polypeptide concentration of feedlot steers.
Pittaluga AM; Ortiz-Fraguada MY; Parker AJ; Relling AE
J Anim Sci; 2022 Sep; 100(9):. PubMed ID: 35830482
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of lipoprotein lipase in transgenic Watanabe heritable hyperlipidemic rabbits improves hyperlipidemia and obesity.
Koike T; Liang J; Wang X; Ichikawa T; Shiomi M; Liu G; Sun H; Kitajima S; Morimoto M; Watanabe T; Yamada N; Fan J
J Biol Chem; 2004 Feb; 279(9):7521-9. PubMed ID: 14660566
[TBL] [Abstract][Full Text] [Related]
19. Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.
Baldassano S; Gasbjerg LS; Kizilkaya HS; Rosenkilde MM; Holst JJ; Hartmann B
Front Endocrinol (Lausanne); 2019; 10():492. PubMed ID: 31447774
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent Insulinotropic Polypeptide (GIP): From prohormone to actions in endocrine pancreas and adipose tissue.
Ugleholdt R
Dan Med Bull; 2011 Dec; 58(12):B4368. PubMed ID: 22142579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
